Prenetics Global Limited announced the formation of a new Prenetics Scientific Advisory Board to provide strategic input based on their scientific knowledge and clinical expertise to help guide the further development of Prenetics' diagnostic cancer genomics platform. Prenetics has been at the forefront of genomic and diagnostic testing, providing a wide range of genetic testing services to individuals and healthcare professionals around the world. The SAB includes a diverse group of highly respected experts in oncology and genomics, each with unique expertise and backgrounds in the field of precision oncology.

Members of the board include Prof. Tony Mok, Prof. Pasi Jänne, Prof. Pan-Chyr Yang, Dr. Hua-Chien Chen, Dr. Frank Ong, and Dr. Lawrence Tzang. Prenetics' SAB appointees include: Prof. Tony S. K. Mok: Prof. Mok will lead the SAB and currently serves as Chairman of the Department of Clinical Oncology of Chinese University of Hong Kong, is a non-executive director of AstraZeneca plc, and an independent director of HUTCHMED (China) Limited. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer.

He was the Principal Investigator and first author on the landmark IRESSA Pan-Asia Study (IPASS). He has also led and co-led multiple studies including the FASTACT 2, IMPRESS, ARCHER 1050, ALEX and AURA 3. He has also engaged in clinical research on ALK positive lung cancer and immunotherapy. The series of clinical trials, led or co-led by him, have defined precision medicine.

His work has been adopted by multiple international guidelines including NCCN, AMP/IASLC/CAP, ASCO and ESMO. Prof. Pasi A. Jänne, MD, PhD: Prof. Pasi Jänne is a globally renowned translational thoracic medical oncologist at the Dana Farber Cancer Institute and Professor of Medicine at Harvard Medical School. He is also the Director of the Lowe Center for Thoracic Oncology and the Director of the Belfer Center for Applied Cancer Science.

His research combines laboratory-based study with translational research in clinical trial of novel therapeutic agents in patients with lung cancer. He has made seminal therapeutic discovery including co-discovery of EGFR mutations and has led the development of therapeutic strategies for patients with EGFR mutant lung cancer. Prof. Pasi Jänne's translational research work also led to the successful development of HER3-ADC in NSCLC and combination with Osimertinib to further enhance the potential efficacy of HER3-ADC.

Prof. Jänne has received multiple awards for his work including from the AACR, ESMO and ASCO. Prof. Pan-Chyr Yang, PhD: Prof. Yang is the former President of Taiwan University and has been a professor in the department of internal medicine at the College of Medicine for 27 years. He has also served as the Director of the Advisory Office for the Ministry of Education and as Dean for the College of Medicine at Taiwan University.

Dr. Yang was honoured with the Joseph W. Cullen Prevention/Early Detection Award at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer. Prof. Yang is a pioneer and leader in pulmonary ultrasound diagnostics and therapeutics that have revolutionized the management of pulmonary diseases which include lung cancer. He has led a research group to develop the method for detection and quantification circulating cancer cells in peripheral blood and to better predict the prognosis and response to treatment for lung cancer patients.

He has led a research group to discover novel genes and pathways that are associated with lung cancer pathogenesis and progression. Dr. Hua-Chien Chen, PhD: He is the Co-founder and the Chief Scientific Officer of ACT Genomics. He has more than 20 years of experience in cancer biology, genomics and drug discovery.

He earned his PhD in Biochemistry from National Yang-Ming University in Taiwan and completed his postdoctoral training in Molecular Biology at Case Western Reserve University in the USA. In 1998, he was an Assistant Investigator at the National Health Research Institute. He then joined TaiGen Biotechnology as the Biology Director.

From 2006 to 2014, he took up a position as Associate Professor at Chang Gung University, where he established a multiplexed micro-RNA quantification platform for the Molecular Medicine Research Center. This platform was developed to identify non-invasive biomarkers for cancer and other diseases. He has extensive experience in the biotech industry, technology-based project evaluation and license negotiation.

Dr. Chen is also an accomplished scientist and acknowledged expert in the fields of molecular biology, oncology and genomics. Dr. Frank S. Ong, MD: Dr. Frank Ong, MD. Chief Medical Officer for Prenetics and Interim CEO for ACT Genomics is a seasoned physician-scientist in Clinical Development and Medical Affairs with clinical fellowship specialization in medical genetics and sub-specialization in clinical molecular genomics laboratory testing for hereditary oncology, common and rare hereditary adult and pediatric conditions, pharmacogenetics, carrier screening, and women's health.

Prior to joining Prenetics as Group Chief Medical Officer, he was the Chief Medical Officer and Chief Scientific Officer of Everly Health and held previous leadership roles in Guardant Health, Illumina and Roche. Dr. Ong led the first FDA 510(k) cleared NGS-based assay and NGS platform in 2013 as well as the first at-home COVID test to obtain Emergency Use Authorization by the US FDA in 2020. He received his Medical Doctorate at the Keck School of Medicine of the University of Southern California in 2002, and completed his residency and fellowship at the University of California, Los Angeles and Cedars-Sinai Medical Center before serving on the faculty at Cedars-Sinai Medical Center.

Dr. Lawrence T.C. Tzang, PhD: Dr. Lawrence Tzang is the Co-Founder of Prenetics and has served as its Chief Scientific Officer and director since its founding in 2014. He has more than 20 years of experience in molecular diagnostics, genomics as well as laboratory automation. Dr. Tzang has been a registered Medical Laboratory Technologist I at the Board of Medical Laboratory Technologist since 2013, a founding member and ex-secretary at the Hong Kong Society for Behavioral and Neural Genetics in 2011-2022 and a fellow of the Hong Kong Society for Molecular Diagnostic Sciences since 2008.

Dr. Tzang received his Ph.D. in Molecular Biology in 2003 and post-doctoral research fellowship at Department of Biology & Chemistry of the City University of Hong Kong from 2003 to 2009. Dr. Tzang has also developed a biochip based genotyping platform for human papillomavirus genotyping and prevalence analysis in cervical cancer. In addition, he also participated in deep proteome profiling of sera from never-smoked lung cancer patients.